Literature DB >> 7543883

Conjugates of synthetic cyclic peptides elicit bactericidal antibodies against a conformational epitope on a class 1 outer membrane protein of Neisseria meningitidis.

P Hoogerhout1, E M Donders, J A van Gaans-van den Brink, B Kuipers, H F Brugghe, L M van Unen, H A Timmermans, G J ten Hove, A P de Jong, C C Peeters.   

Abstract

Bactericidal antibodies directed against surface loops of class 1 outer membrane proteins play a crucial role in protection against meningitis and sepsis caused by Neisseria meningitidis. So far, all efforts to obtain protective antibodies against these apparently conformational epitopes by using linear peptide analogs have been in vain. In this study, conjugates of head-to-tail cyclic peptides encompassing the predicted top of a protective surface loop were used for immunization. A series of 18 cyclic peptides with a ring size ranging from 7 to 17 residues, conjugated to tetanus toxoid, was investigated. Antipeptide and anti-whole-cell immunoglobulin G (IgG) titers elicited by the conjugates were determined. Conjugates of three peptides, containing 14, 15, and 17 amino acid residues (peptides 7, 12, and 13, respectively), induced an anti-whole-cell titer when Quillaja saponin A was used as the adjuvant. When alum was used as the adjuvant, the conjugate of peptide 12 did not elicit an anti-whole-cell response. From the Quillaja saponin A group, some of the sera obtained with conjugates of peptides 7 and 12 and all sera obtained with the peptide 13 conjugate were bactericidal in vitro. None of the sera evoked with alum as the adjuvant showed bactericidal activity. Nonbactericidal sera contained IgG1 primarily, whereas bactericidal sera showed significant titers of IgG2a and IgG2b. Class 1 protein-derived synthetic cyclic peptides which are capable of eliciting bactericidal antibodies, such as peptide 13 derived from meningococcal strain H44/76, represent potential candidates for a (semi)synthetic vaccine against meningococcal disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543883      PMCID: PMC173479          DOI: 10.1128/iai.63.9.3473-3478.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  Antigenic properties and protective capacity of a cyclic peptide corresponding to site A of influenza virus haemagglutinin.

Authors:  S Muller; S Plaué; J P Samama; M Valette; J P Briand; M H Van Regenmortel
Journal:  Vaccine       Date:  1990-08       Impact factor: 3.641

2.  Immunization with synthetic peptides containing epitopes of the class 1 outer-membrane protein of Neisseria meningitidis: production of bactericidal antibodies on immunization with a cyclic peptide.

Authors:  M Christodoulides; B T McGuinness; J E Heckels
Journal:  J Gen Microbiol       Date:  1993-08

3.  Isolation of Neisseria meningitidis mutants deficient in class 1 (porA) and class 3 (porB) outer membrane proteins.

Authors:  J Tommassen; P Vermeij; M Struyvé; R Benz; J T Poolman
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

4.  Antibodies reactive with native lysozyme elicited by a completely synthetic antigen.

Authors:  R Arnon; E Maron; M Sela; C B Anfinsen
Journal:  Proc Natl Acad Sci U S A       Date:  1971-07       Impact factor: 11.205

5.  Solid phase synthesis of partially protected and free peptides containing disulphide bonds by simultaneous cysteine oxidation-release from 2-chlorotrityl resin.

Authors:  K Barlos; D Gatos; S Kutsogianni; G Papaphotiou; C Poulos; T Tsegenidis
Journal:  Int J Pept Protein Res       Date:  1991-12

6.  Human immunoglobulin G subclass immune response to outer membrane antigens in meningococcal group B vaccine.

Authors:  E Wedege; T E Michaelsen
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

7.  Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting.

Authors:  E Wedege; L O Frøholm
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

8.  Simultaneous multiple synthesis and selective conjugation of cyclized peptides derived from a surface loop of a meningococcal class 1 outer membrane protein.

Authors:  H F Brugghe; H A Timmermans; L M Van Unen; G J Ten Hove; G Van de Werken; J T Poolman; P Hoogerhout
Journal:  Int J Pept Protein Res       Date:  1994-02

9.  Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.

Authors:  J C de Moraes; B A Perkins; M C Camargo; N T Hidalgo; H A Barbosa; C T Sacchi; I M Landgraf; V L Gattas; H de G Vasconcelos; I M Gral
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

10.  Identification of T cell epitopes occurring in a meningococcal class 1 outer membrane protein using overlapping peptides assembled with simultaneous multiple peptide synthesis.

Authors:  E J Wiertz; J A van Gaans-van den Brink; H Gausepohl; A Prochnicka-Chalufour; P Hoogerhout; J T Poolman
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

View more
  11 in total

1.  Bovine herpesvirus 1 UL49.5 protein inhibits the transporter associated with antigen processing despite complex formation with glycoprotein M.

Authors:  Andrea D Lipińska; Danijela Koppers-Lalic; Michał Rychłowski; Pieter Admiraal; Frans A M Rijsewijk; Krystyna Bieńkowska-Szewczyk; Emmanuel J H J Wiertz
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  Neisseria meningitidis native outer membrane vesicles containing different lipopolysaccharide glycoforms as adjuvants for meningococcal and nonmeningococcal antigens.

Authors:  Jerry C Nagaputra; Christine S Rollier; Manish Sadarangani; J Claire Hoe; Ojas Hrakesh Mehta; Gunnstein Norheim; Muhammad Saleem; Hannah Chan; Jeremy P Derrick; Ian Feavers; Andrew J Pollard; E Richard Moxon
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

3.  Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity.

Authors:  P van der Ley; L Steeghs; H J Hamstra; J ten Hove; B Zomer; L van Alphen
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

4.  Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: influence of adjuvants on the immune response.

Authors:  L Steeghs; B Kuipers; H J Hamstra; G Kersten; L van Alphen; P van der Ley
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

5.  Function of neisserial outer membrane phospholipase a in autolysis and assessment of its vaccine potential.

Authors:  Martine P Bos; Boris Tefsen; Pierre Voet; Vincent Weynants; Jos P M van Putten; Jan Tommassen
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

6.  Predicting peptide vaccine candidates against H1N1 influenza virus through theoretical approaches.

Authors:  Martiniano Bello; Rafael Campos-Rodriguez; Saul Rojas-Hernandez; Arturo Contis-Montes de Oca; José Correa-Basurto
Journal:  Immunol Res       Date:  2015-05       Impact factor: 2.829

7.  The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Authors:  Nicos Karasavvas; Erik Billings; Mangala Rao; Constance Williams; Susan Zolla-Pazner; Robert T Bailer; Richard A Koup; Sirinan Madnote; Duangnapa Arworn; Xiaoying Shen; Georgia D Tomaras; Jeffrey R Currier; Mike Jiang; Craig Magaret; Charla Andrews; Raphael Gottardo; Peter Gilbert; Timothy J Cardozo; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Robert Paris; Kelli Greene; Hongmei Gao; Sanjay Gurunathan; Jim Tartaglia; Faruk Sinangil; Bette T Korber; David C Montefiori; John R Mascola; Merlin L Robb; Barton F Haynes; Viseth Ngauy; Nelson L Michael; Jerome H Kim; Mark S de Souza
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-04       Impact factor: 2.205

8.  Liposomal meningococcal B vaccination: role of dendritic cell targeting in the development of a protective immune response.

Authors:  Carmen Arigita; Lisette Bevaart; Linda A Everse; Gerben A Koning; Wim E Hennink; Daan J A Crommelin; Jan G J van de Winkel; Martine J van Vugt; Gideon F A Kersten; Wim Jiskoot
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

9.  Inhibition and Reversal of Microbial Attachment by an Antibody with Parasteric Activity against the FimH Adhesin of Uropathogenic E. coli.

Authors:  Dagmara I Kisiela; Hovhannes Avagyan; Della Friend; Aachal Jalan; Shivani Gupta; Gianluca Interlandi; Yan Liu; Veronika Tchesnokova; Victoria B Rodriguez; John P Sumida; Roland K Strong; Xue-Ru Wu; Wendy E Thomas; Evgeni V Sokurenko
Journal:  PLoS Pathog       Date:  2015-05-14       Impact factor: 6.823

10.  LOS oligosaccharide modification enhances dendritic cell responses to meningococcal native outer membrane vesicles expressing a non-toxic lipid A.

Authors:  Hannah E Jones; Alastair Copland; Hendrik Jan Hamstra; Jonathan Cohen; Jeremy Brown; Nigel Klein; Peter van der Ley; Garth Dixon
Journal:  Cell Microbiol       Date:  2013-11-06       Impact factor: 3.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.